Key Advances in Endometrial Cancer

EP. 1: Endometrial Cancer Incidence and Risk Classification

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

January 29th 2021

EP. 2: Genomic Assessments for Metastatic Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

January 29th 2021

EP. 3: Treatment Challenges: Advanced Endometrial Cancer

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 4: Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 5: Second-Line Checkpoint Inhibitor for MSI-H Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 6: GARNET Clinical Trial Regimen in Advanced Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 7: Rationale for Combination Therapy in Advanced EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 8: Safety/Efficacy Results From EC Cohort of KEYNOTE-146

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 9: Impact of Pembrolizumab/Lenvatinib Approval in EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 10: Therapy Sequencing Through Multiple Lines of Therapy in EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 11: Novel Strategies in Development for EC Management

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 12: Promising Novel Targets for Endometrial Cancer Management

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 13: Case 2 Discussion and Considerations for Second-Line Treatment Selection

ByThomas Cluzeau, MD, PhD,Guillermo Garcia-Manero, MD,Rami D. Komrokji, MD,Sanam Loghavi, MD,Uwe Platzbecker, MD

February 16th 2023

The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.

Key Advances in Endometrial Cancer

EP. 1: Endometrial Cancer Incidence and Risk Classification

EP. 2: Genomic Assessments for Metastatic Disease

EP. 3: Treatment Challenges: Advanced Endometrial Cancer

EP. 4: Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

EP. 5: Second-Line Checkpoint Inhibitor for MSI-H Disease

EP. 6: GARNET Clinical Trial Regimen in Advanced Disease

EP. 7: Rationale for Combination Therapy in Advanced EC

EP. 8: Safety/Efficacy Results From EC Cohort of KEYNOTE-146

EP. 9: Impact of Pembrolizumab/Lenvatinib Approval in EC

EP. 10: Therapy Sequencing Through Multiple Lines of Therapy in EC

EP. 11: Novel Strategies in Development for EC Management

EP. 12: Promising Novel Targets for Endometrial Cancer Management

EP. 13: Case 2 Discussion and Considerations for Second-Line Treatment Selection

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL